Taisho Pharmaceutical (OTCMKTS:TAIPY) Downgraded by The Goldman Sachs Group

The Goldman Sachs Group lowered shares of Taisho Pharmaceutical (OTCMKTS:TAIPY) from a neutral rating to a sell rating in a research note released on Monday, The Fly reports.

Shares of TAIPY stock opened at $16.87 on Monday. Taisho Pharmaceutical has a 1 year low of $12.11 and a 1 year high of $19.40. The business’s fifty day moving average is $16.40 and its 200-day moving average is $15.63.

Taisho Pharmaceutical Company Profile

Taisho Pharmaceutical Holdings Co, Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments.

Further Reading: Forex